Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.
Tonstad
Serena
S
Department of Preventive Cardiology, Oslo University Hospital Ullevål, Oslo, Norway. johan.vandewalle@ugent.be
Davies
Simon
S
Flammer
Martina
M
Russ
Cristina
C
Hughes
John
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D001552:Benzazepines / Q000009:adverse effects* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced* / Q000453:epidemiology; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000009:adverse effects* / Q000627:therapeutic use*; D010919:Placebos; D011810:Quinoxalines / Q000009:adverse effects* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012306:Risk; D012893:Sleep Wake Disorders / Q000139:chemically induced; D016540:Smoking Cessation / Q000379:methods; D000068580:Varenicline
D001552:Benzazepines; D018722:Nicotinic Agonists; D010919:Placebos; D011810:Quinoxalines; D000068580:Varenicline